|
|
Volumn 38 Suppl 5, Issue , 2002, Pages
|
|
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
IMATINIB;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
BLAST CELL CRISIS;
CHRONIC MYELOID LEUKEMIA;
DOSE RESPONSE;
HUMAN;
MYELOID LEUKEMIA;
PATHOLOGY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
RECURRENT DISEASE;
REVIEW;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BLAST CRISIS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ENZYME INHIBITORS;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE;
PIPERAZINES;
PYRIMIDINES;
RECURRENCE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 4243926785
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/s0959-8049(02)80606-2 Document Type: Review |
|
Times cited : (32)
|
|
References (24)
|
